{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:23:10Z","timestamp":1755224590426,"version":"3.43.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Angelman syndrome is a neurogenetic disorder resulting from the loss of expression of the ubiquitin-protein ligase E3A gene on chromosome 15. Problematic behaviors including attention-deficit\/hyperactivity disorder (ADHD) symptoms of hyperactivity, impulsivity and inattention are highly prevalent in Angelman syndrome. The efficacy, safety and tolerability of stimulant medications in children with Angelman syndrome for the treatment of ADHD symptoms have not been previously reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We describe three boys with Angelman syndrome who were treated with open-label stimulant medications for ADHD symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Stimulant medications were highly intolerable, and treatment had to be discontinued after limited dosing in all three cases due to marked increases in hyperactivity and impulsivity along with worsened distractibility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings of this study suggest that stimulant medications may be ineffective and poorly tolerated in children with Angelman syndrome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ypg.0000000000000307","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T21:00:06Z","timestamp":1640552406000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Stimulant intolerance in children with Angelman syndrome with hyperactivity: a case series"],"prefix":"10.1097","volume":"32","author":[{"given":"Christopher J.","family":"Keary","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston"},{"name":"Lurie Center for Autism, Lexington"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P.","family":"Thom","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston"},{"name":"Lurie Center for Autism, Lexington"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston"},{"name":"Lurie Center for Autism, Lexington"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng0997-75","article-title":"Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons.","volume":"17","author":"Albrecht","year":"1997","journal-title":"Nat Genet"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.0098","article-title":"Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit\/hyperactivity disorder: emerging concepts from new data.","volume":"17","author":"Arnsten","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajmg.a.30154","article-title":"Behavioral aspects of Angelman syndrome: a case control study.","volume":"132A","author":"Berry","year":"2005","journal-title":"Am J Med Genet"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/TACG.S57386","article-title":"Angelman syndrome: review of clinical and molecular aspects.","volume":"7","author":"Bird","year":"2014","journal-title":"Appl Clin Genet"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/ejhg.2014.93","article-title":"Clinical utility gene card for: Angelman Syndrome.","volume":"23","author":"Buiting","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ajmg.1320560213","article-title":"Clinical profile of Angelman syndrome at different ages.","volume":"56","author":"Buntinx","year":"1995","journal-title":"Am J Med Genet"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1352\/0895-8017(2000)105<0025:PBAWQA>2.0.CO;2","article-title":"Problem behaviors associated with 15q- Angelman syndrome.","volume":"105","author":"Clarke","year":"2000","journal-title":"Am J Ment Retard"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1469-8749.2001.tb00746.x","article-title":"Angelman syndrome: evolution of the phenotype in adolescents and adults.","volume":"43","author":"Clayton-Smith","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/pch\/pxy113","article-title":"ADHD in children and youth: Part 2-treatment.","volume":"23","author":"Feldman","year":"2018","journal-title":"Paediatr Child Health"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pediatrneurol.2010.06.003","article-title":"Atomoxetine for attention deficit hyperactivity disorder in mental retardation.","volume":"43","author":"Fern\u00e1ndez-Ja\u00e9n","year":"2010","journal-title":"Pediatr Neurol"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00148581-200911030-00005","article-title":"Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.","volume":"11","author":"Garnock-Jones","year":"2009","journal-title":"Paediatr Drugs"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"A randomized double-blind study of atomoxetine versus placebo for attention-deficit\/hyperactivitry disorder symptoms in children with autism spectrum disorder.","volume":"51","author":"Harfterkamp","year":"2012","journal-title":"J Am Acad Child Adoelsc Psychiatry"},{"key":"R15-20250812","article-title":"Parent description of anxiety in Angelman syndrome.","author":"Keary","year":"2021","journal-title":"J. Autism Dev Disord"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajmg.a.36864","article-title":"Angelman syndrome in adulthood.","volume":"167A","author":"Larson","year":"2015","journal-title":"Am J Med Genet A"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s13311-015-0361-y","article-title":"Angelman Syndrome.","volume":"12","author":"Margolis","year":"2015","journal-title":"Neurotherapeutics"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","article-title":"Atomoxetine in adults with ADHD: two randomized placebo-controlled studies","volume":"53","author":"Michelson","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/ajmg.a.61642","article-title":"Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome.","volume":"182","author":"Pereira","year":"2020","journal-title":"Am J Med Genet A"},{"key":"R20-20250812","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R21-20250812","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ajmg.a.61140","article-title":"Maladaptive behaviors in individuals with Angelman syndrome.","volume":"179","author":"Sadhwani","year":"2019","journal-title":"Am J Med Genet A"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release gaufnacine for hyperactivity in children with autism spectrum disorder.","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatry"},{"key":"R23-20250812","first-page":"1475","article-title":"How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.","volume":"165","author":"Schachter","year":"2001","journal-title":"CMAJ"},{"issue":"Pt 2","key":"R24-20250812","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2788.1995.tb00477.x","article-title":"Behaviour problems in Angelman syndrome.","volume":"39","author":"Summers","year":"1995","journal-title":"J Intellect Disabil Res"},{"key":"R25-20250812","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pediatrneurol.2012.09.015","article-title":"Neurologic manifestations of Angelman syndrome.","volume":"48","author":"Thibert","year":"2013","journal-title":"Pediatr Neurol"},{"key":"R26-20250812","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","article-title":"Unmet clinical needs and burden in Angelman syndrome: a review of the literature.","volume":"12","author":"Wheeler","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R27-20250812","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1056-4993(18)30108-1","article-title":"The stimulants revisited.","volume":"9","author":"Wilens","year":"2000","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"R28-20250812","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajmg.a.31074","article-title":"Angelman syndrome 2005: updated consensus for diagnostic criteria.","volume":"140","author":"Williams","year":"2006","journal-title":"Am J Med Genet A"},{"key":"R29-20250812","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nn.2327","article-title":"Ube3a is required for experience-dependent maturation of the neocortex.","volume":"12","author":"Yashiro","year":"2009","journal-title":"Nat Neurosci"}],"container-title":["Psychiatric Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YPG.0000000000000307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:01:04Z","timestamp":1755032464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/YPG.0000000000000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ypg.0000000000000307","relation":{},"ISSN":["0955-8829"],"issn-type":[{"type":"print","value":"0955-8829"}],"subject":[],"published":{"date-parts":[[2021,12,15]]}}}